M. Locatelli-Sanchez

897 total citations
17 papers, 303 citations indexed

About

M. Locatelli-Sanchez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, M. Locatelli-Sanchez has authored 17 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in M. Locatelli-Sanchez's work include Lung Cancer Treatments and Mutations (7 papers), Occupational and environmental lung diseases (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). M. Locatelli-Sanchez is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Occupational and environmental lung diseases (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). M. Locatelli-Sanchez collaborates with scholars based in France, Switzerland and Italy. M. Locatelli-Sanchez's co-authors include S. Couraud, M. Duruisseaux, Marie Perier‐Muzet, Pauline Corbaux, Amélie Boespflug, Stéphane Dalle, Denis Maillet, Julien Péron, Pierre-Jean Souquet and D. Arpin and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Respiratory Journal.

In The Last Decade

M. Locatelli-Sanchez

16 papers receiving 297 citations

Peers

M. Locatelli-Sanchez

PRM

ONCOL

EPIDE

IMMUN

SURGE

Shih‐Hong Li Taiwan

Keizo Sugimachi Japan

Sujay Srinivas India

Mitsuhiro Kamimura Japan

Annika Kurreck Germany

Jun Dong China

G. Michetti Italy

Prabhat Bhargava India

Tomohiro Suzumura Japan

Shih‐Hong Li Taiwan

M. Locatelli-Sanchez

239 ×1.3

PRM

128 ×0.7

ONCOL

40 ×1.2

EPIDE

5 ×0.2

IMMUN

27 ×1.1

SURGE

Citations per year, relative to M. Locatelli-Sanchez M. Locatelli-Sanchez (= 1×) peers Shih‐Hong Li

Countries citing papers authored by M. Locatelli-Sanchez

Since Specialization

Citations

This map shows the geographic impact of M. Locatelli-Sanchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Locatelli-Sanchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Locatelli-Sanchez more than expected).

Fields of papers citing papers by M. Locatelli-Sanchez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Locatelli-Sanchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Locatelli-Sanchez. The network helps show where M. Locatelli-Sanchez may publish in the future.

Co-authorship network of co-authors of M. Locatelli-Sanchez

This figure shows the co-authorship network connecting the top 25 collaborators of M. Locatelli-Sanchez. A scholar is included among the top collaborators of M. Locatelli-Sanchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Locatelli-Sanchez. M. Locatelli-Sanchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Freymond, N., Florent Wallet, Thomas Gilbert, et al.. (2023). High flow nasal oxygen in frail COVID-19 patients hospitalized in intermediate care units and non-eligible to invasive mechanical ventilation. Respiratory Medicine and Research. 84. 101026–101026. 1 indexed citations

2.

Chu, Quincy S., Maria Carmela Piccirillo, Laurent Greillier, et al.. (2023). IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.. Journal of Clinical Oncology. 41(17_suppl). LBA8505–LBA8505. 18 indexed citations

3.

Locatelli-Sanchez, M., et al.. (2022). Tracheal stent aspergillosis occurring after aortic allograft of the trachea. Transplant Infectious Disease. 24(6). e13965–e13965. 1 indexed citations

4.

Maillet, Denis, Pauline Corbaux, Jean‐Jacques Stelmes, et al.. (2020). Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. European Journal of Cancer. 132. 61–70. 56 indexed citations

5.

Mazières, Julien, Jacques Cadranel, Bénédicte Mastroïanni, et al.. (2020). Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study. Respiratory Medicine and Research. 77. 58–66. 2 indexed citations

6.

Corbaux, Pauline, Denis Maillet, Amélie Boespflug, et al.. (2019). Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. European Journal of Cancer. 121. 192–201. 58 indexed citations

7.

Zalcman, Gérard, Julien Mazières, Laurent Greillier, et al.. (2019). Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD). Annals of Oncology. 30. v747–v747. 16 indexed citations

8.

Amini‐Adlé, Mona, B. Balme, M. Locatelli-Sanchez, P.-J. Souquet, & Stéphane Dalle. (2018). Éruption lichénoïde cutanéo-muqueuse sous anti-PD-1. Annales de Dermatologie et de Vénéréologie. 145(11). 725–727.

9.

Zalcman, Gérard, Julien Mazières, Laurent Greillier, et al.. (2017). Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Annals of Oncology. 28. v648–v648. 12 indexed citations

10.

Paris, Christophe, Pascal Dô, Bénédicte Mastroïanni, et al.. (2017). Association between lung cancer somatic mutations and occupational exposure in never-smokers. European Respiratory Journal. 50(4). 1700716–1700716. 12 indexed citations

11.

Scherpereel, Arnaud, Laurent Greillier, Pascal Dô, et al.. (2017). Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.. Journal of Clinical Oncology. 35(15_suppl). LBA8507–LBA8507. 12 indexed citations

12.

Scherpereel, Arnaud, Laurent Greillier, Pascal Dô, et al.. (2017). Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.. Journal of Clinical Oncology. 35(18_suppl). LBA8507–LBA8507. 33 indexed citations

13.

Souquet, Pierre Jean, S. Couraud, & M. Locatelli-Sanchez. (2016). Les cancers bronchiques non à petites cellules de stade IV Hors addiction oncogénique : 1re ligne et maintenance. Revue des Maladies Respiratoires Actualités. 8(5). 351–360. 1 indexed citations

14.

Gérinière, L., et al.. (2015). Croyances des patients envers les thérapies ciblées orales et leur influence sur l’observance dans le cancer broncho-pulmonaire : une étude pilote prospective. Revue de Pneumologie Clinique. 72(1). 25–34. 7 indexed citations

15.

Avrillon, Virginie, M. Locatelli-Sanchez, Laure Folliet, et al.. (2015). Lung Cancer May Increase Serum Procalcitonin Level. Infectious Disorders - Drug Targets. 15(1). 57–63. 33 indexed citations

16.

Locatelli-Sanchez, M., S. Couraud, & P.-J. Souquet. (2015). Épidémiologie du cancer bronchique : données actuelles. Revue des Maladies Respiratoires Actualités. 7(4). 285–289. 1 indexed citations

17.

Locatelli-Sanchez, M., S. Couraud, D. Arpin, et al.. (2013). Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes. Lung. 191(5). 491–499. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact